FDA authorizes Novavax's updated protein-based COVID vaccine, distinguishing it from other shots

The FDA has authorized Novavax's protein-based COVID-19 vaccine, providing Americans with an alternative to mRNA-based shots for the fall booster campaign. The vaccine, which has already received CDC approval, uses a traditional protein subunit-based design and targets the spike protein of the omicron subvariant. While head-to-head clinical data on its efficacy against circulating variants is not available, accumulated data suggests it is similarly effective to mRNA vaccines. The vaccine will be available to everyone aged 12 and up, and Novavax expects it to be available in thousands of locations nationwide.